Measures for promoting the rational use of medicines in the 27 EU Member States were surveyed in a report by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute).
Survey on rational use of medicines in 27 EU Members States
Home/Reports
|
Posted 22/04/2011
0
Post your comment
Their results showed that there are many different practices between the different Member States in the EU with regard to generic medicine policies. An overview is given in the table below:
For example, while most countries (22) advocate international non-proprietary name (INN) prescribing, relatively few (4) have made this obligatory, whereas generic substitution by the pharmacist is practiced in the majority of countries (21).
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Related articles
The EU and rational use of medicines
The Netherlands and rational use of medicines
Italy’s rational use of medicines
France’s rational use of medicines
Germany’s rational use of medicines
Rational use of medicines in Denmark
Promoting rational use of medicines in Europe
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Central America moves toward joint evaluation of biosimilar medicines
Home/Reports Posted 22/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment